Drug Profile

Tinlarebant - Belite Bio

Alternative Names: aka LBS-008; BPN-14967; LBS-008

Latest Information Update: 02 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Columbia University
Developer Belite Bio
Class Eye disorder therapies; Fluorinated hydrocarbons; Ketones; Piperidines; Pyrazoles; Pyridines; Small molecules
Mechanism of Action RBP4 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Stargardt disease
New Molecular Entity Yes

Highest Development Phases

Phase III Dry macular degeneration; Stargardt disease

Most Recent Events

02 Jun 2025 9443135: Updated KDM and designation table
21 May 2025 Tinlarebant - Belite Bio receives Breakthrough Therapy status for Stargardt disease in USA
14 Feb 2025 Phase-III clinical trials in Dry macular degeneration in Czech Republic (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com